“Craig Jordan is an unusual young man. A very unusual young man.” These words, written by Jordan’s grammar school science teacher in an attempt to gain him an interview at the University of Leeds after an admittedly mediocre early academic career, characterized much of his life, both professional and personal. It was an unusual young man who, at the beginning of his scientific career, envisioned that a failed oral contraceptive (ICI 46474 aka tamoxifen) could be a breast cancer treatment and who went on to demonstrate the therapeutic properties of tamoxifen that are widely accepted today. The Jordan laboratory identified improved survival outcomes with longer durations of tamoxifen treatment, the increased risk of endometrial carcinoma in postmenopausal women receiving tamoxifen, and the utility of tamoxifen as a chemoprevention agent—all of which were findings that were confirmed in landmark clinical trials but that were quite controversial when they first emerged from...

You do not currently have access to this content.